新型循环作为治疗炎症性疾病的双联素-23抑制剂
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
ACS medicinal chemistry letters
|April 16, 2025
概括
新的循环可以有效地抑制INTERLEUKIN-23 (IL-23),为炎症状况提供潜在的治疗方法,如炎症性肠病 (IBD). 这一发现推动了对IL-23相关疾病的治疗策略.
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 介素-23 (IL-23) 是一种关键的细胞因子,涉及各种炎症和自身免疫性疾病.
- IL-23信号的失调有助于诸如炎症性肠病 (IBD) 等疾病的发病.
研究的目的:
- 披露新型循环,旨在抑制互乐金-23 (IL-23) 的活性.
- 为这些呈现潜在的治疗应用,特别是在IL-23介导疾病的背景下.
主要方法:
- 该研究涉及到由公式I表示的循环的设计和插图.
- 专利申请详细说明了这些新型化合物的化学结构和抑制性质.
主要成果:
- 描述的循环体显示出强烈的干乐素-23 (IL-23) 抑制.
- 这些化合物对由IL-23驱动的疾病具有显著的治疗前景.
- 特别关注的是它们在治疗炎症性肠病 (IBD) 中的潜在疗效.
结论:
- 开发的循环是一种有前途的新型治疗药物,向IL-23.3.
- 这些发现为管理包括IBD在内的炎症性疾病提供了潜在的新途径.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
100
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
100
01:24T Cell Types and Functions
633
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
633
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
105
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
105
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
87
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
87
01:29Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80